EEV-001 / INOVIQ - LARVOL DELTA

iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers. (PubMed, Front Immunol) - "Direct evidence for iPSC-derived CAR-NK EV/sEV therapy in NSCLC is currently unavailable...Major unresolved issues include rapid systemic clearance and sequestration by hepatic and splenic components of the mononuclear phagocyte system, route-dependent pulmonary deposition, mucus and mucociliary clearance, pulmonary macrophage uptake, subtype- and lesion-specific antigen heterogeneity, EV identity and purity, CAR-positive vesicle quantification, potency-adjusted manufacturing yield, lot comparability, and the absence of potency assays validated across laboratories or linked to clinical outcomes. Thus, iPSC-CAR-NK sEVs should currently be viewed as an investigational translational concept rather than a clinically ready NSCLC therapy."

Journal • Review • Graft versus Host Disease • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy. (PubMed, J Vis Exp) - "The platform has been validated using CAR-NK-EVs and CAR-T-EVs for both hematological and solid tumor cell lines. The CAR-EV platform represents a promising approach for the rapid development of off-the-shelf therapeutic CAR-EVs tailored to specific disease indications, with the potential to reduce adverse side effects associated with CAR-cell-based therapies."

Journal • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor

INOVIQ reports 88% kill rate of breast and lung cancer cells in CAR-exosome therapy study (Small Caps) - "INOVIQ...has reported superior efficacy from an in vitro study of CAR-exosomes cancer therapy that killed almost 88% of triple-negative breast cancer (TNBC) and lung cancer cells within 96 hours. Real-time cell analysis demonstrated that CAR-NK-EVs — chimeric antigen receptor natural killer cells derived from extracellular vesicles — exerted a significant cytotoxic effect on TNBC and non-small-cell lung cancer (Calu-3) cells compared to control treatments. Data from three independent experiments showed that treatment with 2.5 million CAR-NK-EVs resulted in 87.8% cell death in TNBC and Calu-3 cells respectively within four days."

Preclinical • Non Small Cell Lung Cancer • Triple Negative Breast Cancer

INOVIQ study confirms breakthrough exosome therapy in the treatment of breast cancer (Small Caps) - "Biotechnology company INOVIQ...has produced and isolated engineered exosomes (EEVs) to target and kill breast cancer cells in vitro using its proprietary EXO-ACE technology...The breakthrough therapy has been validated in a proof-of-concept study in which a chimeric antigen receptor (CAR) was developed for the targeted delivery of therapeutic EEVs to cancer cells...The breast cancer-targeting CAR was expressed in modified exosomes released by immune cells...The study showed that 75% of breast cancer cells underwent cell death within 72 hours when treated with the exosomes....It also demonstrated that exosomes can be engineered and loaded with drug cargo such as RNA (ribonucleic acid) therapeutics to target and deliver effective treatments for neurological diseases across the blood-brain barrier."

Preclinical • Breast Cancer • Oncology • Solid Tumor